Record revenues and profits were achieved with a 77% revenue increase and 151% rise in operating income year-over-year, driven by new product launches and strong market share in key generics. The company maintains a robust balance sheet, low debt, and is evaluating M&A and Nasdaq uplisting options.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.